GRI Bio

GRI Bio P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of GRI Bio (GRI) as of Nov 4, 2026 is -0.33. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -0.39 — a change of -15.49% (higher).

P/FCF

-0.33

YoY

-15.49%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of GRI Bio is 2025 -0.33 . P/FCF (Price-to-Free-Cash-Flow Ratio) of GRI Bio was 2024 -0.39 . It decreases by -15.49% higher compared to the previous year.

The GRI Bio P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-1.41 USD
Jan 1, 2019
-1.16 USD
Jan 1, 2020
-0.90 USD
Jan 1, 2021
-0.40 USD
Jan 1, 2022
-3.07 USD
Jan 1, 2023
-0.37 USD
Jan 1, 2024
-0.39 USD
Jan 1, 2025
-0.33 USD
The GRI Bio P/FCF history
YEARP/FCFYoY
-0.33-15.49%
-0.39+4.49%
-0.37-87.91%
-3.07+663.97%
-0.40-55.39%
-0.90-22.23%
-1.16-17.70%
-1.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GRI Bio Stock analysis

What does GRI Bio do? GRI Bio, Inc. generates revenue through the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company focuses on advancing a pipeline of Natural Killer T (NKT) modulating therapies, including its lead program GRI-0621, a small molecule RAR-beta dual agonist for Idiopathic pulmonary fibrosis (IPF) treatment. GRI-0621 is formulated as a once-daily oral capsule targeting multiple fibrotic indications. The firm also develops GRI-0803, a novel activator of human Type 2 NKT cells for autoimmune disorders, initially targeting systemic lupus erythematosus. Additionally, GRI Bio holds a library of 500+ proprietary compounds addressing high-value indications with unmet medical needs. GRI Bio's primary customers are pharmaceutical companies and healthcare providers seeking innovative treatments for complex diseases. The company's lead asset GRI-0621 is positioned for clinical development in IPF, while GRI-0803 targets systemic lupus erythematosus. The firm's proprietary compound library supports potential partnerships and licensing agreements for high-value therapeutic areas. The company's business model relies on advancing its pipeline through clinical trials and securing strategic collaborations for drug development and commercialization. The company's revenue streams include potential licensing fees from pharmaceutical partners, milestone payments upon achieving clinical or regulatory milestones, and future royalties from commercialized products. GRI Bio's focus on NKT modulating therapies for inflammatory, fibrotic, and autoimmune diseases positions it to address significant unmet medical needs in these therapeutic areas. The firm's pipeline includes GRI-0621 for IPF and GRI-0803 for systemic lupus erythematosus, with additional compounds targeting other high-value indications. GRI Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GRI Bio stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of GRI Bio is -0.33 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of GRI Bio changed from -0.39 to -0.33, representing a -15.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) GRI Bio since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s GRI Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GRI Bio

All Key Metrics — GRI Bio